FTC on class actions
This article was originally published in The Rose Sheet
Executive SummaryFederal courts reviewing class action "coupon" settlements should be required to determine the "realistic value of the coupons to the class," commission says in Feb. 15 letter to U.S. Judicial Conference's Committee on Rules of Practice & Procedure. Coupons complicate a court's ability to analyze proposed settlements because "unlike monetary settlements, they are difficult to value" and "many factors come into play in such valuation, including the likelihood that consumers will actually use the coupon." FTC suggests courts should consider history of coupon redemption rates in similar situations, whether all class members will be entitled to use coupons, time restrictions on redemption...
You may also be interested in...
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.